Time to Initiation of Symptomatic Treatment in untreated Parkinson Disease

Lead Investigator: Octavian Adam, Albany Medical College
Title of Proposal Research: Time to Initiation of Symptomatic Treatment in untreated Parkinson Disease
Vivli Data Request: 8729
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Parkinson disease (PD) is a progressive degenerative disease that affects the brain. It is the second most common after Alzheimer’s disease, and it affects approximately 1% of individuals over the age of 60, or between 500,000 and 1 milion Americans. There is no cure or treatment to delay progression in PD. The development of treatments relies on accurately tracking its natural progression. Because progression of symptoms in PD is generally slow, most individuals with this condition will not need symptomatic treatment right from the beginning after they are diagnosed. The start of symptomatic treatment represents a “milestone” for an individual with PD, because it means that their symptoms have progressed to a certain level of disability requiring symptomatic relief. All patients with PD eventually start symptomatic treatment, which makes this clinical milestone of treatment initiation an important measure of disease progression, frequently used in clinical trials. Understanding what best predicts this meaningful disease progression milestone is important in the design of clinical trials because most of them enroll individuals with PD that have never been on medications for PD. The aim of this analysis is to find individual and disease characteristics that best predict the time to the initiation of symptomatic treatment in individuals with PD previously untreated.

Requested Studies:

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease (SPARK)
Data Contributor: Biogen
Study ID: NCT03318523
Sponsor ID: N/A